MAP2K1 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 20 of 834 results for "MAP2K1"
i
  1. PAGE: Global Reference Panel dbGaP

    ID: phs001033.v1.p1

    Description: onal related individuals from the Americas in the Human Genome Diversity Panel (H952) plus all additional samples from the Americas A subset of the unrelated individuals from the Maasai in Kinyawa, Kenya (MKK) dataset from the International Hapmap Project hosted at Coriell Additional samples will be available for restricted use with a data access agreement with the Bustamante Lab. This study is part of the Population Architecture using Genomics and Epidemiology (PAGE) study (phs000356)....

    Study Types: Control Set

  2. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery PDB

    ID: PDB:5BX0

    Description: Dual specificity mitogen-activated protein kinase kinase 1

  3. Crystal structure of human p38alpha MAP kinase PDB

    ID: PDB:3HVC

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  4. Crystal structure of human ERK2 complexed with a MAPK docking peptide PDB

    ID: PDB:2Y9Q

    Description: MITOGEN-ACTIVATED PROTEIN KINASE 1 (E.C.2.7.11.24),

  5. Structural basis of autoactivation of p38 alpha induced by TAB1 (Tetragonal crystal form) PDB

    ID: PDB:4LOP

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24), TGF-beta-

  6. Human p38 MAP Kinase in Complex with RL24 PDB

    ID: PDB:3HV5

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  7. Human p38 MAP Kinase in Complex with a Benzylpiperazin-Pyrrol PDB

    ID: PDB:3IW6

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  8. Structure of Inactive Human p38 MAP Kinase in Complex with a Thiazole-Urea PDB

    ID: PDB:3IW8

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  9. Human p38 MAP Kinase in Complex with Scios-469 PDB

    ID: PDB:3HUB

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  10. MP2K2_HUMAN UniProt:Swiss-Prot

    ID: P36507

    Description: Dual specificity mitogen-activated protein kinase kinase 2

  11. Human p38 MAP Kinase in Complex with RL116 PDB

    ID: PDB:3LFE

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  12. Human p38 MAP Kinase in Complex with RL113 PDB

    ID: PDB:3LFD

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  13. Structural basis of autoactivation of p38 alpha induced by TAB1 (Monoclinic crystal form) PDB

    ID: PDB:4LOO

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24), TGF-beta-

  14. Crystal structure of p38delta kinase PDB

    ID: PDB:3COI

    Description: Mitogen-activated protein kinase 13 (E.C.2.7.11.24)

  15. MP2K1_HUMAN UniProt:Swiss-Prot

    ID: Q02750

    Description: Removed Dual specificity mitogen-activated protein kinase kinase 1

  16. Human p38 MAP Kinase in Complex with RL98 PDB

    ID: PDB:3LFB

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  17. Human p38 MAP Kinase in Complex with RL166 PDB

    ID: PDB:3LFF

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.11.24)

  18. Human P38 MAP Kinase in Complex with Inhibitor 1a PDB

    ID: PDB:1ZYJ

    Description: Mitogen-activated protein kinase 14 (E.C.2.7.1.37)

  19. Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma ArrayExpress

    ID: E-GEOD-50509

    Description: utations (n=3, 8%), BRAF amplification (n=3, 8%), MEK1/2 mutations (n=3, 8%) and an AKT1 mutation (n=1, 3%). Four Progs tumours displayed multiple resistance mechanisms, and four patients with multiple Progs demonstrated inter-tumoral heterogeneity of resistance mechanisms. Six (21%) of 29 Progs showed loss of MAPK activity by gene expression analysis. These MAPK-inhibited Progs had unknown resistance mechanisms, and these patients had a shorter progression-free survival than patients with MAPK re-activated Progs. There were no responses to subsequent targeted therapy, even when the identified mechanism of resistance was predicted to be responsive. Heterogeneity of resistance mechanisms was common between patients, within patients and within individual tumors. The MAPK pathway remained inhibited in a subset of resistant tumors with unknow...

  20. Targeting β-catenin overcomes resistance to MEK inhibitor in PIK3CA mutant colon cancer ArrayExpress

    ID: E-GEOD-71981

    Description: Mitogen-activated protein kinases (MEK 1/2) are central...


Displaying 20 of 834 results for "MAP2K1"